Updated survival results of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastatic colorectal cancer (mCRC).
Toshio Otsuji
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Kentaro Yamazaki
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Hitoshi Ojima
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Hiroyuki Kuwano
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Takeshi Kato
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical
Ken Shimada
Honoraria - Taiho Pharmaceutical
Tadamichi Denda
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Taito Esaki
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Ichinosuke Hyodo
Consultant or Advisory Role - Taiho Pharmaceutical; Yakult Honsha
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Narikazu Boku
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha